NuVasive (NUVA) Issues FY19 Earnings Guidance

NuVasive (NASDAQ:NUVA) updated its FY19 earnings guidance on Wednesday. The company provided EPS guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.47. The company issued revenue guidance of $1.14-1.16 billion, compared to the consensus revenue estimate of $1.17 billion.NuVasive also updated its FY 2019 guidance to $2.20-2.30 EPS.

A number of analysts recently commented on the company. Zacks Investment Research lowered NuVasive from a hold rating to a sell rating in a research report on Wednesday, February 13th. Jefferies Financial Group lowered NuVasive from a buy rating to a hold rating and set a $60.00 target price for the company. in a research report on Tuesday, February 12th. Cantor Fitzgerald reaffirmed a hold rating and issued a $50.00 target price on shares of NuVasive in a research report on Monday, February 11th. Needham & Company LLC lowered NuVasive from a buy rating to a hold rating in a research report on Friday, February 8th. Finally, BTIG Research decreased their target price on NuVasive to $59.00 and set a buy rating for the company in a research report on Thursday, January 17th. They noted that the move was a valuation call. Four analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. NuVasive has a consensus rating of Hold and an average price target of $64.35.

Get NuVasive alerts:

NUVA traded up $1.85 during midday trading on Thursday, reaching $57.27. 1,563,872 shares of the company were exchanged, compared to its average volume of 931,905. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.83 and a current ratio of 3.45. The firm has a market capitalization of $2.95 billion, a P/E ratio of 29.98, a P/E/G ratio of 1.58 and a beta of 1.12. NuVasive has a one year low of $43.51 and a one year high of $72.41.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Wednesday, February 20th. The medical device company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.06. The firm had revenue of $288.30 million during the quarter, compared to analyst estimates of $290.85 million. NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.56 EPS. On average, equities analysts forecast that NuVasive will post 2.18 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

See Also: How a Strangle Strategy is different from a Straddle Strategy

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Leave a Reply

Your email address will not be published. Required fields are marked *